Onco Actu du 8 juillet 2015

	1. Biologie
Passenger Mutations Can Skew Results [The Scientist] Some genetically engineered mice harbor unwanted mutations that hitchhike alongside desired modifications, affecting experimental outcomes.
	3.5 Prévention - UV
Indoor tanning rates dropping [Reuters] We think the increasing awareness about the dangers of indoor tanning may be partly responsible for the decrease in indoor tanning,” said lead author Gery P. Guy Jr., a health economist at the CDC in Atlanta.
	4.12 Biopsies liquides
Toward Blood-based Cancer Detection [The Scientist] Circulating tumor cells, exosomes, and DNA can improve the diagnosis of many cancers. But are liquid biopsies ready for prime time?
	4.9 Dép., diag. & prono. - Sein
More Mammograms May Not Always Mean Fewer Cancer Deaths [NPR] The medical community has come to accept that overdiagnosis exists, Elmore says. "This is something that wasn't even considered when I was in med school years ago. We're slowly realizing that we are taking healthy people and maybe potentially giving them harm."
Here's new evidence that widespread breast cancer screening isn't effective [Vox] The authors of the newest study don't advocate no screening. Instead, they note that the benefits of screening will probably be more favorable when screening is directed at people with a high risk of the disease — such as those with a family history of breast cancer.
Breast screening does not reduce cancer deaths, international study warns [The Guardian] The latest salvo in the war over breast cancer screening, however, threatens to reopen the debate. Leading cancer epidemiologists have gone back to the original trials carried out in Sweden in the 1960s and 1970s. Those trials found that screening could prevent 20-25% of breast cancer deaths. In a paper in the Journal of the Royal Society of Medicine, the experts say the methodology of the study was wrong and that figure is far too high.
Benefits of breast cancer screening overestimated [The Telegraph] Experts at Kings College London and the University of Strathclyde claim that former studies have failed to take into account the huge advances in breast cancer treatment which are largely responsible for the increase in survival rates.
	5.2 Pharma
Prima Biomed (PBMD) Stock Spikes on European Regulatory Feedback for Breast Cancer Drug [TheStreet] Shares are up 23.36% to $1.47 in morning trading on Tuesday after the biotech company announced that it received positive advice from the European drug regulatory agency concerning the development of its lead metastatic breast cancer candidate IMP321.
	5.2.3 Pharma - économie
Insurer M&A endangers pharma's pricing power, particularly in cancer: Moody's [FiercePharma] The biggest pressure point? High-cost cancer drugs, the ratings agency figures, not just because they're costly, but because so many companies now depend on that category.
	5.3.4 Traitements - AMM (FDA, EMA)
Lilly cancer drug improves survival, raises blood clot risk: FDA [Reuters] Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots, according to a preliminary review by the U.S. Food and Drug Administration.
	6.1 Observation
More men with prostate cancer are opting for surveillance [Reuters] For the new study, Cooperberg and his coauthor Dr. Peter Carroll used data from 10,472 men with localized prostate cancer treated at 45 U.S. urology practices between 1990 and 2013.
	6.7 DMP, Big Data & applis
Making sense of big cancer data [Cancer Research UK] “Cancers contain many more mutations than we thought – but finding those that actually matter is like finding a needle in a haystack,” Dr Dana Pe’er told the audience at the annual Big Data Analytics Conference held at the British Library this month.
Kevin Fitzpatrick Named CEO of CancerLinQ LLC [ASCO] Mr. Fitzpatrick was instrumental in the creation and implementation of the Diabetes Collaborative Registry™, the first global, cross-specialty clinical diabetes registry designed to track and improve the quality of diabetes and metabolic care across the primary care and specialty care continuum.
Genome researchers raise alarm over big data [Nature News & Comment] Storing and processing genome data will exceed the computing challenges of running YouTube and Twitter, biologists warn.
	6.9 Controverses
Separating science and science politics? [The Mermaid's Tale] Occasionally a new idea, technology, method, or, today, 'omic, does come along, and there is a swell of momentum as the herd rushes to adopt it. Again, however, the goal is to establish too-big-to-stop longterm projects.